<?xml version="1.0" encoding="UTF-8"?><protocol_summary><protocol><id>13318</id><no>VULVIE</no><status>Open</status><title>A randomized controlled trial of Vulvar fractionated CO2-Laser therapy with and without concomitant topical clobetasol propionate 0.05% ointment for treatment of Vulvar lichen sclerosus</title><objective>This is a randomized double-blind placebo-controlled trial design to determine whether combining FxCO2-laser with the traditional therapy of clobetasol propionate 0.05% ointment (combined treatment) as compared to FxCO2-laser and placebo ointment (FxCO2-laser only) will improve treatment response in women undergoing FxCO2-laser for vulvar lichen sclerosus.&#xD;
&#xD;
Primary objective: To evaluate if women with LS who undergo FxCO2 laser therapy and concomitant TCS (clobetasol group) have higher treatment success (defined as a MCID of a &amp;#8805;16 point improvement in Skindex-29 questionnaire) than those who undergo FxCO2 laser and placebo ointment (placebo group).&#xD;
&#xD;
Hypothesis: A higher proportion of women randomized to clobetasol will achieve treatment success as compared to those randomized to placebo.&#xD;
Approach: The proportion of women in each cohort who obtain a &amp;#8805;16 point improvement in Skindex-29 validated questionnaire score from baseline to final visit will be compared.&#xD;
Secondary objectives: To compare change in pre- and post-treatment scores on validated questionnaires measuring vulvovaginal symptoms, sexual function, lower urinary tract function, and genital self-image between the clobetasol group compared to the placebo group.&#xD;
&#xD;
Hypothesis: Women randomized to clobetasol will demonstrate an equal or greater improvement on validated quality of life questionnaires measuring vulvovaginal symptoms, sexual function, lower urinary tract function, and genital self-image as compared to women randomized to placebo.&#xD;
Approach: Change scores will be calculated to determine change per participant over the treatment period and mean change scores will be compared between cohorts.</objective><nct_id>NCT04951206</nct_id><sponsor_type>Institutional</sponsor_type><age_group>Adult</age_group><treatment_type>Treatment</treatment_type><treatment>Device: Fractionated CO2-laser&#xD;
Drug: Clobetasol Propionate 0.05% Ointment</treatment><phase>IV</phase><disease_site>Other</disease_site><lay_description>This study investigates the follow condition or disease: Vulvar Lichen Sclerosus</lay_description><PI>Dieter, Alexis</PI><institution>Medstar Washington Hospital Center</institution><management_group>MedStar Medical &amp; Surgical Research Network</management_group></protocol><sipVersion>2026.1.0 Build 16</sipVersion><copyright> &lt;a href="https://advarra.com" target="_blank"&gt;&amp;copy; 2026 Advarra, Inc.&lt;/a&gt; </copyright></protocol_summary>